Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | DIAGONAL BIO AB: Diagonal Bio publishes Year-End Report for 2024 | 1 | Cision News | ||
21.03. | DIAGONAL BIO AB: Diagonal Bio granted patent in Japan | 1 | Cision News | ||
19.03. | Nomination Committee change in Diagonal Bio AB (publ.) | 1 | Cision News | ||
19.03. | DIAGONAL BIO AB: Trading in Diagonal Bio's shares and warrants of series TO 2 on NGM Nordic SME begins today | 1 | Cision News | ||
DIAGONAL BIO Aktie jetzt für 0€ handeln | |||||
18.03. | NGM MARKET NOTICE: #25-27 Warrants issued by Diagonal Bio AB approved for listing at NGM | 2 | Cision News | ||
14.03. | NGM MARKET NOTICE: #25-23 Diagonal Bio AB approved for listing at NGM | 1 | Cision News | ||
13.03. | DIAGONAL BIO AB: Stall Courant and Diagonal Bio agree to a pilot test of LAMPlify® | 1 | Cision News | ||
04.03. | Diagonal Bio AB: Diagonal Bio has been approved for delisting from Nasdaq First North Growth Market | 113 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that Nasdaq has approved Diagonal Bio's application for delisting from Nasdaq First North Growth Market ("First North"). The... ► Artikel lesen | |
04.03. | Diagonal Bio AB: Diagonal Bio has received conditional approval for listing on NGM Nordic SME | 117 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has received conditional approval for listing on NGM Nordic SME ("NGM"). The first day of trading is planned for 19 March 2025. This means that... ► Artikel lesen | |
03.03. | DIAGONAL BIO AB: Diagonal Bio applies for change of marketplace to NGM Nordic SME | 1 | Cision News | ||
19.02. | Diagonal Bio AB's announces last day of trading in BTU and first day of trading in warrants of series TO 2 | 2 | Cision News | ||
18.02. | Diagonal Bio AB resolves on a directed issue of units to all external underwriters | 4 | Cision News | ||
12.02. | DIAGONAL BIO AB: Diagonal Bio's CEO Karin Wehlin increases ownership | 1 | Cision News | ||
07.02. | Diagonal Bio AB: Diagonal Bio AB's rights issue of units oversubscribed | 270 | GlobeNewswire (Europe) | The subscription period in Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units of initially approximately SEK 6.0 million ended on 6 February 2025 (the "Rights Issue"). The Rights... ► Artikel lesen | |
05.02. | DIAGONAL BIO AB: Stall Goop conducts pilot test of LAMPlify® | 1 | Cision News | ||
29.01. | Diagonal Bio AB: Diagonal Bio announces positive pilot test results and secures order from StallZet | 72 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowned horse trainer at StallZet. The order comes as a result of... ► Artikel lesen | |
23.01. | The subscription period of Diagonal Bio AB's rights issue of units commences today | 1 | Cision News | ||
22.01. | Diagonal Bio AB: Diagonal Bio AB publishes investment memorandum prior to upcoming rights issue of units | 155 | GlobeNewswire (Europe) | The subscription period of Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units, which was resolved on 23 December 2024 by the Board of Directors together with the resolution on... ► Artikel lesen | |
17.01. | DIAGONAL BIO AB: Nomination Committee change in Diagonal Bio (publ.) | 2 | Cision News | ||
17.01. | Bulletin from the Extraordinary General Meeting of Diagonal Bio AB on 17 January 2025 | 2 | Cision News |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
INTELLIA THERAPEUTICS | 6,144 | -6,23 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with ... | CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,066 | -1,90 % | PacBio Appoints Jim Gibson As New CFO | WASHINGTON (dpa-AFX) - Life science technology company PacBio, Inc. (PACB) announced Thursday the appointment of Jim Gibson as the company's new Chief Financial Officer, effective as of his... ► Artikel lesen | |
CENTOGENE | 0,120 | 0,00 % | Centogene NV: CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 12, 2025 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company") today announced it has closed its transaction to sell... ► Artikel lesen | |
ATAI LIFE SCIENCES | 1,121 | -11,25 % | ATAI Life Sciences Aktie: Bericht über jüngste Finanztrends | Das Biotechnologie-Unternehmen erforscht innovative Substanzen gegen Depressionen und entwickelt neuartige Behandlungsmethoden für psychische Erkrankungen. ATAI Life Sciences treibt die Entwicklung... ► Artikel lesen | |
BIOMERIEUX | 115,40 | +0,52 % | bioMérieux receives FDA 510(k) Clearance for its VITEK COMPACT PRO, a new ID/AST system to fight against antimicrobial resistance | MARCY L'ÉTOILE, France, March 18, 2025 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration... ► Artikel lesen | |
CYCLACEL | 0,296 | -100,00 % | Cyclacel Pharmaceuticals, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
SYROS PHARMACEUTICALS | 0,029 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
XTL BIOPHARMACEUTICALS | 1,060 | +6,53 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
GENUS | 22,200 | 0,00 % | Genus Appoints Andy Russell As Chief Financial Officer | LONDON (dpa-AFX) - Genus Plc (GNS.L), a biotechnology company, said on Thursday that it has appointed Andy Russell as Chief Financial Officer with effect from August 1 to succeed Alison Henriksen... ► Artikel lesen | |
ANAPTYSBIO | 17,300 | +0,58 % | AnaptysBio, Inc.: Anaptys Announces Stock Repurchase Plan | SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that... ► Artikel lesen | |
ABIONYX PHARMA | 1,208 | -0,49 % | CIC Market Solutions Initiates Buy Coverage of ABIONYX Pharma | Regulatory News:
ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), next-generation biopharma dedicated to the development of innovative biomedicines based on recombinant apolipoprotein apoA-I... ► Artikel lesen | |
MEIRAGTX | 6,400 | +2,40 % | MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy | As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal dystrophy, LCA4, benefited substantially from unilateral subretinal administration of rAAV8.hRKp.AIPL1 with improved... ► Artikel lesen | |
METABOLIC EXPLORER | 0,095 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 09.10.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 09.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 09.10.2024ISIN NameAU0000064966 VIRG.MON.... ► Artikel lesen | |
AKESO | 10,800 | +17,39 % | Akeso, Inc.: Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies | Key Highlights:
Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline... ► Artikel lesen | |
MAAT PHARMA | 6,500 | +8,70 % | MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients' Responses to Immunotherapies | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen |